Avelumab has been filed for use in patients ... Merck Inc and Pfizer had seemed like outsiders in the immunotherapy race just two years ago, when PD-1 inhibitors Merck’s Keytruda and BMS ...

The precise use of immunotherapy agents in locally advanced head and neck squamous cell carcinoma has not been clearly ...

Avelumab is described as a human anti-programmed ... I and preliminary Phase II data from the trial at the Society for Immunotherapy of Cancer (SITC) 39th annual meeting. This data showed ...

Merck KGaA and Pfizer have got the fourth checkpoint inhibitor to market after the US regulator approved their avelumab for a rare form of skin cancer. The FDA’s approval of avelumab ...

TG4001— Poster presentation details: Title: “Randomized Phase II trial evaluating the combination of TG4001, an HPV16 therapeutic cancer vaccine and avelumab in patients with immunotherapy ...

ICI-based therapy included administration of any of the following drugs during treatment: Nivolumab, pembrolizumab, atezolizumab, ipilimumab, tremelimumab, durvalumab, or avelumab. Primary ...

A novel immunotherapy approach developed by Ludwig ... combining these CV1-producing T cells with cancer-targeting antibodies such as avelumab and cetuximab further improved the ability of ...

VXM01 is an oral immunotherapy that trains T cells to attack tumor blood ... Treatment with the investigational oral vaccine VXM01 in combination with Bavencio (avelumab) demonstrated both safety and ...

According to the study design, no regular maintenance treatment with avelumab was planned in the comparator arm for patients who were progression-free following chemotherapy. However, maintenance ...

The company will also present a poster on randomized Phase II data of TG4001 in combination with avelumab in the cervical cancer subgroup. The 2025 American Society of Clinical Oncology (ASCO), annual ...